A research paper issued in the October 2023 Edition of Lancet Global Health analyses the cost of tuberculosis diagnosis and treatment households in low income countries, providing evidence for the need to reduce economic barriers to treatment.
Summary
Background
People accessing and completing treatment for tuberculosis can face large economic costs, even when treatment is provided free of charge. The WHO End TB Strategy targets the elimination of catastrophic costs among tuberculosis-affected households. While low-income and middle-income countries (LMICs) represent 99% of global tuberculosis cases, only 29 of 135 LMICs had conducted national surveys of costs for patients with tuberculosis by December, 2022. We estimated costs for patients with tuberculosis in countries that have not conducted a national survey, to provide evidence on the economic burden of tuberculosis in these settings and inform estimates of global economic burden.
Methods
We extracted data from 22 national surveys of costs faced by patients with tuberculosis that were completed across 2015–22 and met inclusion criteria. Using a Bayesian meta-regression approach, we used these data and covariate data for all 135 LMICs to estimate per-patient costs (2021 US$) by cost category (ie, direct medical, direct non-medical, and indirect), country, drug resistance, and household income quintile. We also estimated the proportion of households experiencing catastrophic total costs (defined as >20% of annual household income) as a result of tuberculosis disease.
Findings
Across LMICs, mean direct medical costs incurred by patients with tuberculosis were estimated as US$211 (95% uncertainty interval 154–302), direct non-medical costs were $512 (428–620), and indirect costs were $530 (423–663) per episode of tuberculosis. Overall, per-patient costs were $1253 (1127–1417). Estimated proportions of tuberculosis-affected households experiencing catastrophic total costs ranged from 75·2% (70·3–80·0) in the poorest quintile to 42·5% (34·3–51·5) in the richest quintile, compared with 54·9% (47·0–63·2) overall.
Interpretation
Tuberculosis diagnosis and treatment impose substantial costs on affected households. Eliminating these economic losses is crucial for removing barriers to accessing tuberculosis diagnosis and completing treatment among affected households and achieving the targets set in WHO’s End TB Strategy.
